Today’s Stock On Watch: Biondvax Pharmaceuticals Limited Ads (NASDAQ:BVXV) Has Decline in Shorts

November 28, 2016 - By Darrin Black   ·   0 Comments

Today's Stock On Watch: Biondvax Pharmaceuticals Limited Ads (NASDAQ:BVXV) Has Decline in Shorts

The stock of Biondvax Pharmaceuticals Limited Ads (NASDAQ:BVXV) registered a decrease of 12.07% in short interest. BVXV’s total short interest was 20,400 shares in November as published by FINRA. Its down 12.07% from 23,200 shares, reported previously. With 2,200 shares average volume, it will take short sellers 9 days to cover their BVXV’s short positions. The short interest to Biondvax Pharmaceuticals Limited Ads’s float is 0.63%. About 642 shares traded hands. BiondVax Pharmaceuticals Ltd (ADR) (NASDAQ:BVXV) has declined 12.88% since April 25, 2016 and is downtrending. It has underperformed by 18.89% the S&P500.

BiondVax Pharmaceuticals Ltd is an Israel biopharmaceutical company. The company has a market cap of $11.65 million. The Firm holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. It has a 114 P/E ratio. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.

Another recent and important BiondVax Pharmaceuticals Ltd (ADR) (NASDAQ:BVXV) news was published by Benzinga.com which published an article titled: “IPO Outlook: Galapagos Offers New Hope For CF And RA Sufferers” on May 12, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Darrin Black


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>